Abstract:Background Some data, albeit controversial, suggest people with chronic myeloid leukaemia (CML) presenting in accelerated phase have the same prognosis as people with CML presenting in chronic phase but with high-risk co-variates. Objectives Interrogate the heterogeneity of subjects presenting in accelerated phase and compare their outcomes with persons presenting in high-risk chronic phase. Methods We interrogated data from 2132 consecutive subjects ≥ 18 years with CML presenting in accelerated (N = 274) or chronic phase (N = 1858). Subjects were seen at Peking University People's Hospital from January, 2006 to June, 2023. Criteria for accelerated phase according to the European LeukemiaNet (ELN) 2020 criteria included: ≥ 1 of the following: (1) blood or bone marrow blasts ≥ 15% but < 30%; (2) blood basophils ≥ 20%; and (3) platelet concentration < 100 × 10E + 9/L unrelated to therapy. Chronic phase was defined according to the ELN 2020 criteria. For subjects in chronic phase ELTS score at diagnosis was calculated and used to classify subjects into risk cohorts. Transformation was defined as blood or bone marrow blasts ≥ 30% during TKI-therapy. Transformation-free survival (TFS) was calculated as the interval from starting TKI-therapy to transformation, death or censored at a transplant or last follow-up. We then compared therapy responses and outcomes between defined accelerated phase cohorts and chronic phase risk cohorts using competing risk models and Kaplan-Meier survival analyses. Cox regression analyses were used to further explore the co-variates associated with therapy responses and outcomes. Results Amongst the 274 subjects presenting in accelerated phase 205 (75%), 39 (14%) and 31 (11%) were classified based on basophilia, excess blasts or thrombocytopenia. Amongst the 1858 subjects presenting in chronic phase 1220 (66%), 461 (25%) and 176 (9%) were ELTS low-, intermediate- and high-risk. In multi-variable analyses we use chronic phase subjects in ELTS low-, intermediate- and high-risk cohort as reference. Subjects in accelerated phase with basophilia had better therapy responses (MMR, HR = 1.2 [1.0, 1.5], p = 0.05; MR 4, HR = 1.7 [1.3, 2.2], p < 0.001; MR 4.5, HR = 2.0 [1.5, 2.6], p < 0.001) and similar TFS and survival (TFS, HR = 0.9 [0.5, 1.6], p = 0.60; survival, HR = 1.4 [0.6, 3.2], p = 0.45) compared with the ELTS intermediate-risk cohort. Accelerated phase subjects with excess blasts and with thrombocytopenia therapy responses like chronic phase subjects with the ELTS intermediate- and high-risk cohorts. TFS and survival were similar with ELTS high-risk cohort. These comparisons held in subjects receiving initial imatinib-therapy but were less clear in subjects receiving initial 2 nd generation TKI therapy. Similar findings were also obtained using the WHO 2016 criteria. Conclusions Subjects presenting in accelerated phase defined by basophilia had better therapy responses but similar TFS and survival compared with subjects presenting in chronic phase in the ELTS intermediate-risk cohort. Subjects presenting in accelerated phase with excess blasts or thrombocytopenia had comparable therapy responses compared with subjects presenting in chronic phase in the ELTS intermediate- and high-risk cohorts whereas their TFS and survival were like those or worse compared with subjects presenting in chronic phase in the ELTS high-risk cohort. The implication of our findings is presenting in accelerated phase per se does not always confer a worse prognosis compared with subjects presenting in chronic phase.

[Retrospective Cohort Study on the Prognosis of Chronic Myeloid Leukemia].

Karyotypic Analysis and Prognosis for 41 Patients with Chronic Myelomonocytic Leukemia

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Real‐world Data of Chronic Myelomonocytic Leukemia: A Chinese Single‐center Retrospective Study

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

A Nomogram for Predicting T315i-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multicenter Retrospective Study

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia

Prognostic Analysis of Chronic Myeloid Leukemia in Chinese Population in an Imatinib Era

The Lost or Absence of MRD < 0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Clinical Characteristics,treatment Pattern,and Outcomes in Newly Diagnosed Patients with Chronic Myeloid Leukemia in the Chronic Phase by Age

Prognostic Factors in Chronic Myelomonocytic Leukemia: A Retrospective Analysis of 41 Patients

[Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome]

[Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].

[Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].

Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 109/L

Prognostic Variables in Newly Diagnosed Children with Acute Myeloid Leukemia: AML-XH-99.

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

[Analysis of Prognostic Variables in Childhood Acute Myeloid Leukemia].

[Minimal Residual Disease Level Predicts Outcomes in the Non-Favorable Risk Patients with Acute Myeloid Leukemia].